AimMax® Therapeutics, Inc. (AimMax), is a company engaged in the research and development of biopharmaceuticals at various stages through in-licensing, our discovery efforts, or co-development with strategic partners.
The company was founded in 2017 by pharmaceutical R&D professionals with diverse and synergistic backgrounds.
Clinical Trial Design and Operations
Regulatory and Commercial Strategies
Passion and Dedication
To advance early-stage molecules, from lead optimization to clinical proof of principle by understanding the molecules, the science and disease models.
To incorporate innovative trial design and data analysis to maximize clinical trial efficiency and the success of pivotal trials.
To position the product for optimal labeling and commercial potential.
To benefit the patients and health care community.
Discovery and early development of novel or improved anti-infectives against resistant bacteria, fungi, and other microorganisms.
Our cutting edge anti-inflammatory, anti-bacterial, and anti-infective products are quickly progressing through target identification, lead selection and optimization, nonclinical and clinical testing phases.
An ophthalmic formulation with enhanced penetration, potent anti-inflammatory activity and reduced dosing frequency for the treatment of inflammation and pain post ocular surgery under the regulatory 505(b)(2) pathway. Currently in Phase 3 clinical development.